Cerebrovascular Disease, Cardiovascular Disease, and Chronic Kidney Disease: Interplays and Influences

Area of Science:

• Nephrology
• Cardiology
• Toxicology

Background:

• Chronic kidney disease (CKD) is associated with significantly elevated cardiovascular disease (CVD) risk.
• Traditional CVD risk factors are insufficient to explain the heightened risk in CKD patients.

Purpose of the Study:

• To review the underlying reasons for high CVD risk in CKD patients.
• To explore alternative therapeutic strategies beyond traditional risk factor management for reducing CVD in CKD.

Main Methods:

• Review of existing literature on uremic toxins and CVD in CKD.
• Analysis of systemic and gut-derived uremic toxins (GDUT).
• Evaluation of potential interventions targeting uremic toxin reduction.

Main Results:

• CKD patients are exposed to systemic uremic toxins (e.g., ADMA, tHcy) and gut-derived uremic toxins (e.g., indoxyl sulfate, TMAO).
• Cyanocobalamin is identified as toxic in CKD patients.
• Interventions like dietary changes, transplantation, intensive dialysis, and specific vitamin therapy (methylcobalamin) show promise.

Conclusions:

• Therapies targeting uremic toxins are essential for managing CVD risk in CKD.
• Reducing uremic toxin levels may offer a novel approach to mitigate CVD in the CKD population.